CYV Shares Ceryvyn Therapeutics Limited
ASX · ASXLast in our picks 2026-10-04 — not in the current list; analysis below is from that screen
Ultra-small-cap biotech with high optionality but limited current investability.
Future value: $0.02 (+36.36%) · 6-12 months
Signal breakdown
- ▸Very low liquidity and early-stage profile.
- ▸Above 50-day MA (+1.2%)
- ▾Near 52-week low (0.5% of range)
- ▸~36% upside to price target
Is CYV a buy right now?
Trend: CYV is trading above the 50-day average (+0.00%), RSI 1 — oversold territory, with a 3-month return of -16.67%.
Valuation & quality: Ceryvyn Therapeutics Limited trades on a trailing P/E of 0.0, PEG 0.65, price-to-book 0.45; fundamentals show net margin 33044500.0%.
Analyst consensus: 1 analysts have a mean 12-month price target of A$0.10 (+900% vs the last close; range A$0.10 – A$0.10), consensus rating “none”.
Our screen: BUY (score 2) — Ultra-small-cap biotech with high optionality but limited current investability.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | -98.30% | +0.00% | +0.00% | +0.00% | +0.00% |
Fundamentals
Analyst price target
Technical signals
About Ceryvyn Therapeutics Limited
Ceryvyn Therapeutics Limited, a biopharmaceutical company, develops biologic therapy for the rare disease lymphangioleiomyomatosis in Australia. The company offers CYV-101, which is in pre-clinical trial stage, an inhaled therapy intended for delivery directly to the lung.
Sector: Healthcare · Industry: Biotechnology · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.